Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Licogliflozin - Novartis Pharmaceuticals

Next Previous
Search
Drug Profile

Licogliflozin - Novartis Pharmaceuticals

Alternative Names: LIK-066

Latest Information Update: 03 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antifibrotics; Antihyperglycaemics; Dioxins; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Discontinued Heart failure; Obesity; Polycystic ovary syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 03 Jan 2024 Novartis Pharmaceuticals terminates the phase II ELIVATE trial in Non-alcoholic steatohepatitis (Monotherapy, Combination therapy) in Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, Estonia, Germany, India, Italy, Japan, Mexico, Puerto Rico, Russia, Singapore, South Africa, South Korea, Spain, Taiwan, Turkey, United Kingdom and USA, due to the sponsor decision (PO, Capsule) (EudraCT2019-002324-32) (JapicCTI205173) (NCT04065841)
  • 02 Jan 2023 Licogliflozin is still in phase II trial for Hepatic fibrosis (Combination therapy) in the USA, Argentina, Belgium, Brazil, Bulgaria, Canada, China, Chile, Colombia, Estonia, Denmark, Germany, India, Israel, Italy, Japan, South Korea, Mexico, Puerto Rico, Russia, Singapore, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Turkey, United Kingdom (NCT04065841) (EudraCT2019-002324-32)
  • 02 Jan 2023 Licogliflozin is still in phase II trial for Hepatic fibrosis (Monotherapy) in the USA, Argentina, Belgium, Brazil, Bulgaria, Canada, China, Chile, Colombia, Estonia, Denmark, Germany, India, Israel, Italy, Japan, South Korea, Mexico, Puerto Rico, Russia, Singapore, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Turkey, United Kingdom (NCT04065841) (EudraCT2019-002324-32)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top